Takeda Pharmaceutical (TAK) FCF Payout Ratio Growth (1y) (2019 - 2026)
Powered by 
Analysis
Takeda Pharmaceutical (TAK) FCF Payout Ratio Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.24 Bn | 623.49 Bn | 17.26 Bn | -59.92% |
| 2 | AbbVie | 443.24 Bn | 436.67 Bn | 12.70 Bn | 65.46% |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | -41.69% |
| 4 | Novartis Ag | 266.33 Bn | 258.64 Bn | 11.24 Bn | 30.28% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn | -44.83% |
| 7 | Revolution Medicines | 44.03 Bn | 44.03 Bn | - | - |
| 8 | Incyte | 25.35 Bn | 20.82 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.58 Bn | 18.92 Bn | 683.80 Mn | - |
| 10 | Takeda Pharmaceutical | 2.61 Bn | -3.19 Bn | 5.10 Bn | 49.97% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -49.97% |
| Sep 30, 2025 | 68.66% |
| Jun 30, 2025 | 9.02% |
| Mar 31, 2025 | -27.25% |
| Dec 31, 2024 | 52.52% |
| Sep 30, 2024 | -121.53% |
| Jun 30, 2024 | 35.83% |
| Mar 31, 2024 | 65.26% |
| Dec 31, 2023 | -128.00% |
| Sep 30, 2023 | 12.32% |
| Jun 30, 2023 | 7.34% |
| Mar 31, 2023 | -54.68% |
| Dec 31, 2022 | 10.72% |
| Sep 30, 2022 | 60.35% |
| Jun 30, 2022 | -51.93% |
| Mar 31, 2022 | -164.72% |
| Dec 31, 2021 | 35.97% |
| Sep 30, 2021 | -14.45% |
| Jun 30, 2021 | 14.78% |
| Mar 31, 2021 | 56.32% |